Tech Company Financing Transactions
Camena Bioscience Funding Round
Camena Bioscience, based in Cambridge, secured $9.9 million from MEIF Proof of Concept & Early Stage Fund.
Transaction Overview
Company Name
Announced On
7/3/2023
Transaction Type
Venture Equity
Amount
$9,911,000
Round
Series A
Investors
MEIF Proof of Concept & Early Stage Fund (Lead Investor)
Proceeds Purpose
The company intends to use the funds to scale operations and continue development of its DNA synthesis platform, gSynth.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
The Science Village Chesterford Research Park
Cambridge, CB10 1XL
UK
Cambridge, CB10 1XL
UK
Phone
Undisclosed
Website
Email Address
Overview
Founded in 2016, Camena Bioscience is a synthetic biology company that was born out of ideas from Cambridge and Pasadena. Camena's CEO and co-founder is Steve Harvey, a leader in genomics research, and the CSO and co-founder is Derek Stemple, a world-renowned molecular biologist and previously a co-founder of TwistDX which was acquired by Alere (now a part of Abbott)
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Harvey
Chief Technical Officer
Derek Stemple
Co-Founder
Scott Fraser
Browse more venture capital transactions:
Prev: 7/3/2023: RoboDeck venture capital transaction
Next: 7/3/2023: MyDawa venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs